

Miltenyi Biotec and THSTI to launch India's first CAR-T Cell and Gene Therapy training curriculum

17 July 2025 | News

Ultimately fostering a skilled workforce and enhancing manufacturing capabilities



Miltenyi Biotec, a global leader in cell and gene therapy (CGT) technologies, has signed a Letter of Intent (LoI) with the Translational Health Science and Technology Institute (THSTI), Faridabad, to establish India's first hands-on training programme in clinical cell manufacturing.

This groundbreaking collaboration, initiated by Miltenyi Biotec and certified under the aegis of the Biotechnology Industry Research Assistance Council (BIRAC), aims to bridge India's talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.

The training programme will be hosted at THSTI's GMP facility, with Miltenyi Biotec deploying its cutting-edge automated platforms, including the CliniMACS Prodigy® and MACSQuant® Analyzer.

Participants will receive joint certification and benefit from an immersive, industry-aligned curriculum combining theory with hands-on training in CAR-T cell manufacturing, quality control, and analytics.

By focusing on practical skill development, the programme aims to:

- Build a pipeline of certified CGT professionals

- Enhance the quality and scalability of advanced therapy manufacturing in India
- Support local innovation and access to cutting-edge treatments
- Foster industry-academia partnerships to drive translational research